Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Mar;39(3):790–792. doi: 10.1128/AAC.39.3.790

nfxC-type quinolone resistance in a clinical isolate of Pseudomonas aeruginosa.

H Fukuda 1, M Hosaka 1, S Iyobe 1, N Gotoh 1, T Nishino 1, K Hirai 1
PMCID: PMC162629  PMID: 7793896

Abstract

Quinolone resistance gene nqr-T91 in a clinical isolate of Pseudomonas aeruginosa P1481 was cotransducible with catA1 in P. aeruginosa PAO. The nqr-T91 transductant, PKH-T91, was resistant to norfloxacin, imipenem, and chloramphenicol and showed less norfloxacin accumulation than the parent strain did. Loss of the 46-kDa outer membrane protein (D2) and an increase in the 50-kDa outer membrane protein in PKH-T91 were observed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Lipopolysaccharides in the transductant were also changed. These alterations were considered to be related to lower levels of norfloxacin accumulation in PKH-T91. These genetic and biochemical properties suggested that an nfxC type of quinolone-resistant mutation occurred in a clinical isolate of P. aeruginosa P1481.

Full Text

The Full Text of this article is available as a PDF (218.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acar J. F., Francoual S. The clinical problems of bacterial resistance to the new quinolones. J Antimicrob Chemother. 1990 Oct;26 (Suppl B):207–213. doi: 10.1093/jac/26.suppl_b.207. [DOI] [PubMed] [Google Scholar]
  2. Aubert G., Pozzetto B., Dorche G. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy. J Antimicrob Chemother. 1992 Mar;29(3):307–312. doi: 10.1093/jac/29.3.307. [DOI] [PubMed] [Google Scholar]
  3. Celesk R. A., Robillard N. J. Factors influencing the accumulation of ciprofloxacin in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1989 Nov;33(11):1921–1926. doi: 10.1128/aac.33.11.1921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chamberland S., Bayer A. S., Schollaardt T., Wong S. A., Bryan L. E. Characterization of mechanisms of quinolone resistance in Pseudomonas aeruginosa strains isolated in vitro and in vivo during experimental endocarditis. Antimicrob Agents Chemother. 1989 May;33(5):624–634. doi: 10.1128/aac.33.5.624. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chin N. X., Clynes N., Neu H. C. Resistance to ciprofloxacin appearing during therapy. Am J Med. 1989 Nov 30;87(5A):28S–31S. doi: 10.1016/0002-9343(89)90015-6. [DOI] [PubMed] [Google Scholar]
  6. Cohen S. P., McMurry L. M., Hooper D. C., Wolfson J. S., Levy S. B. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction. Antimicrob Agents Chemother. 1989 Aug;33(8):1318–1325. doi: 10.1128/aac.33.8.1318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Diver J. M., Schollaardt T., Rabin H. R., Thorson C., Bryan L. E. Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy. Antimicrob Agents Chemother. 1991 Aug;35(8):1538–1546. doi: 10.1128/aac.35.8.1538. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Eron L. J., Harvey L., Hixon D. L., Poretz D. M. Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria. Antimicrob Agents Chemother. 1985 Aug;28(2):308–310. doi: 10.1128/aac.28.2.308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fukuda H., Hosaka M., Hirai K., Iyobe S. New norfloxacin resistance gene in Pseudomonas aeruginosa PAO. Antimicrob Agents Chemother. 1990 Sep;34(9):1757–1761. doi: 10.1128/aac.34.9.1757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hancock R. E., Nikaido H. Outer membranes of gram-negative bacteria. XIX. Isolation from Pseudomonas aeruginosa PAO1 and use in reconstitution and definition of the permeability barrier. J Bacteriol. 1978 Oct;136(1):381–390. doi: 10.1128/jb.136.1.381-390.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hirai K., Aoyama H., Suzue S., Irikura T., Iyobe S., Mitsuhashi S. Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12. Antimicrob Agents Chemother. 1986 Aug;30(2):248–253. doi: 10.1128/aac.30.2.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hirai K., Suzue S., Irikura T., Iyobe S., Mitsuhashi S. Mutations producing resistance to norfloxacin in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1987 Apr;31(4):582–586. doi: 10.1128/aac.31.4.582. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hitchcock P. J., Brown T. M. Morphological heterogeneity among Salmonella lipopolysaccharide chemotypes in silver-stained polyacrylamide gels. J Bacteriol. 1983 Apr;154(1):269–277. doi: 10.1128/jb.154.1.269-277.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hooper D. C., Wolfson J. S., Souza K. S., Ng E. Y., McHugh G. L., Swartz M. N. Mechanisms of quinolone resistance in Escherichia coli: characterization of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation. Antimicrob Agents Chemother. 1989 Mar;33(3):283–290. doi: 10.1128/aac.33.3.283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Jakics E. B., Iyobe S., Hirai K., Fukuda H., Hashimoto H. Occurrence of the nfxB type mutation in clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1992 Nov;36(11):2562–2565. doi: 10.1128/aac.36.11.2562. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kresken M., Hafner D., Mittermayer H., Verbist L., Bergogne-Bérézin E., Giamarellou H., Esposito S., van Klingeren B., Kayser F. H., Reeves D. S. Prevalence of fluoroquinolone resistance in Europe. Study Group 'Bacterial Resistance' of the Paul-Ehrlich-Society for Chemotherapy e. V. Infection. 1994;22 (Suppl 2):S90–S98. doi: 10.1007/BF01793572. [DOI] [PubMed] [Google Scholar]
  17. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  18. Legakis N. J., Tzouvelekis L. S., Makris A., Kotsifaki H. Outer membrane alterations in multiresistant mutants of Pseudomonas aeruginosa selected by ciprofloxacin. Antimicrob Agents Chemother. 1989 Jan;33(1):124–127. doi: 10.1128/aac.33.1.124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Masecar B. L., Celesk R. A., Robillard N. J. Analysis of acquired ciprofloxacin resistance in a clinical strain of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1990 Feb;34(2):281–286. doi: 10.1128/aac.34.2.281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Matsumoto H., Nakazawa T., Ohta S., Terawaki Y. Chromosomal locations of catA, pobA, dcu and chu genes in Pseudomonas aeruginosa. Genet Res. 1981 Dec;38(3):251–266. doi: 10.1017/s0016672300020590. [DOI] [PubMed] [Google Scholar]
  21. Matsumoto H., Ohta S., Kobayashi R., Terawaki Y. Chromosomal location of genes participating in the degradation of purines in Pseudomonas aeruginosa. Mol Gen Genet. 1978 Nov 29;167(2):165–176. doi: 10.1007/BF00266910. [DOI] [PubMed] [Google Scholar]
  22. Michea-Hamzehpour M., Lucain C., Pechere J. C. Resistance to pefloxacin in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1991 Mar;35(3):512–518. doi: 10.1128/aac.35.3.512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Michéa-Hamzehpour M., Furet Y. X., Pechère J. C. Role of protein D2 and lipopolysaccharide in diffusion of quinolones through the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1991 Oct;35(10):2091–2097. doi: 10.1128/aac.35.10.2091. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Rella M., Haas D. Resistance of Pseudomonas aeruginosa PAO to nalidixic acid and low levels of beta-lactam antibiotics: mapping of chromosomal genes. Antimicrob Agents Chemother. 1982 Aug;22(2):242–249. doi: 10.1128/aac.22.2.242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Robillard N. J. Broad-host-range gyrase A gene probe. Antimicrob Agents Chemother. 1990 Oct;34(10):1889–1894. doi: 10.1128/aac.34.10.1889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Robillard N. J., Scarpa A. L. Genetic and physiological characterization of ciprofloxacin resistance in Pseudomonas aeruginosa PAO. Antimicrob Agents Chemother. 1988 Apr;32(4):535–539. doi: 10.1128/aac.32.4.535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Scully B. E., Neu H. C., Parry M. F., Mandell W. Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa. Lancet. 1986 Apr 12;1(8485):819–822. doi: 10.1016/s0140-6736(86)90937-2. [DOI] [PubMed] [Google Scholar]
  28. Trias J., Nikaido H. Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1990 Jan;34(1):52–57. doi: 10.1128/aac.34.1.52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Yoshida H., Bogaki M., Nakamura S., Ubukata K., Konno M. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J Bacteriol. 1990 Dec;172(12):6942–6949. doi: 10.1128/jb.172.12.6942-6949.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Yoshida H., Nakamura M., Bogaki M., Nakamura S. Proportion of DNA gyrase mutants among quinolone-resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1990 Jun;34(6):1273–1275. doi: 10.1128/aac.34.6.1273. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES